NewsSTERNA BIOLOGICALS

_____
2018

Company news 2018

  • Successfull device feasibility studies with sterna biologicals asthma drug candidates SB010 enables select of optimal nebulizers for late-stage development and commercialization

    Marburg, Germany, September 05, 2018 

    • Feasibility studies show excellent data with SB010 across a selection of high efficiency hand-held nebulizers
    • Company well positioned to advance SB010 into late-stage clinical development

    Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that the Company has successfully completed in vitro device feasibility studies with its asthma drug candidate, SB010. These studies support the selection of the most efficient and user-friendly device options for late-stage development and commercialization of SB010.

    READ MORE

  • sterna biologicals prepares for phase IIB clinical program with GATA-3 antagonist drug candidates SB010 in asthma and SB012 in ulcerative colitis

    Marburg, Germany, September 05, 2018

    • Key preparatory steps to conduct phase IIb trials initiated, including CMC and regulatory activities in the EU and US
    • Devices for SB010 in asthma selected, oral formulation work for SB012 in ulcerative colitis (UC) started

    Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today provided an update on its preparations for phase IIb clinical development of its GATA-3 antagonist drug candidates SB010 and SB012.

    READ MORE

  • sterna biologicals presents detailed results from successful phase 2a study with GATA-3 specific DNAzyme formulation SB012 in patients with ulcerative colitis

    Marburg, Germany, June 5, 2018

    • Comprehensive data set presented at Digestive Disease Week® in the U.S.
    • SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis
    • Further support of GATA-3 antagonism as promising treatment approach for variety of chronic inflammatory diseases

    sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that the full data set from the successful SECURE study (NCT 02129439), a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with the GATA-3 specific DNAzyme formulation SB012, was presented during an oral session on June 5th at Digestive Disease Week® in Washington, DC.

    READ MORE

  • sterna biologicals announces data with gata-3 specific dnazyme SB012 to be presented at Digestive Disease Week®

    Marburg, Germany, May 29, 2018

    • Further insights and data from Phase 2a trial in ulcerative colitis

    Sterna biologicals GmbH & Co. KG (sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that further insights and data from a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with its DNAzyme candidate SB012 will be presented at Digestive Disease Week® (DDW) in Washington, DC, June 2-5, 2018.

    READ MORE

  • sterna biologicals announces phase IIa data with SB010 published in Respiratory Research

    Marburg, Germany, April 19, 2018

    • Investigator initiated study sponsored and funded by DZL (German Center for Lung Research) in patients with moderate to severe eCOPD
    • Primary endpoint and key secondary endpoints met

    Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that data from a randomized, double-blind, placebo-controlled, multicenter phase IIa trial with SB010 in chronic obstructive pulmonary disease (COPD) patients with eosinophilic airway inflammation have been published in the peer-reviewed medical journal, Respiratory Research[i].

    READ MORE

  • sterna biologicals reports phase 2a study data demonstrating efficacy of its gata 3 specific dnazyme formulation sb012 in patients with ulcerative colitis

    Marburg, Germany, February 19, 2018

    • Data presented at the 13th Congress of ECCO (European Crohn's and Colitis Organisation).
    • SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis. This represents a further validation of GATA-3-antagonism for the treatment of a variety of chronic inflammatory diseases.

    sterna biologicals GmbH & Co. KG ("sterna"), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that positive data from the SECURE study (NCT 02129439), a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with its GATA-3 specific DNAzyme formulation SB012, were presented at the 13th Congress of ECCO (European Crohn's and Colitis Organisation).

    READ MORE

  • sterna biologicals to participate in upcoming international conferences in H1 2018

    Marburg, Germany, 01 February 2018
    sterna biologicals GmbH & Co. KG (sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announces its participation in the following key scientific and partnering conferences in the first half of 2018:

    13th Congress of ECCO - European Crohn's and Colitis Organisation
    Date: February 14-17, 2018 in Vienna, Austria

    READ MORE

  • sterna biologicals appoints Christian Pangratz as Chief Executive Officer

    Marburg, Germany, 8 January 2018

    sterna biologicals GmbH & Co. KG (Sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that the Company has appointed Christian M. Pangratz as Chief Executive Officer. He brings over 25 years of life sciences experience, notably in the areas of strategic planning, corporate and business development, alliance and project management, new product planning, marketing and sales.

    READ MORE